Botulinum toxin for spasticity: a case for change to the Pharmaceutical Benefits Scheme

Med J Aust. 2018 May 21;208(9):379-381. doi: 10.5694/mja17.00841.
No abstract available

Keywords: Neurological rehabilitation.

Publication types

  • Historical Article

MeSH terms

  • Adolescent
  • Australia / epidemiology
  • Botulinum Toxins / administration & dosage*
  • Botulinum Toxins / history
  • Botulinum Toxins / therapeutic use
  • Brain Injuries, Traumatic / epidemiology
  • Brain Injuries, Traumatic / rehabilitation
  • Child
  • Child, Preschool
  • Drug Development / ethics*
  • History, 19th Century
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / economics
  • Muscle Spasticity / epidemiology
  • Muscle Spasticity / rehabilitation
  • Nervous System Diseases / drug therapy*
  • Nervous System Diseases / epidemiology
  • Nervous System Diseases / psychology
  • Nervous System Diseases / rehabilitation
  • Quality of Life

Substances

  • Botulinum Toxins